Rapport Therapeutics
2 known investors
Rapport is a biopharmaceutical company developing novel therapeutics. The company is led by a team with extensive experience in drug discovery, clinical development, and commercialization across neuroscience and rare disease indications.
BiotechHealthtechMedical Devices
Founders & leadership
AC
Abe CeesayPresident
D
David
CG
Cheryl Gault
T
Troy
DS
Dr. Sevigny
S
Swamy
K
Kathy
Investors · 2
In the news
- Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86 - Defense Worlddefenseworld.net · 2026
- How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story - Simply Wall St Newssimplywall.st · 2026
- Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.comca.investing.com · 2026
- [144] Rapport Therapeutics, Inc. SEC Filing | RAPP SEC Filing - Form 144stocktitan.net · 2026
- Leerink initiates Rapport Therapeutics stock with outperform rating By Investing.cominvesting.com · 2026
- Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform » Rapport Therapeuticsrapportrx.com · 2023